menu search

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
― Screening closed for the Phase 3 REACH pivotal trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) ― ― Expect to report topline data for REACH in the fourth quarter of 2024 ― ― Interactions continue with the U.S. Food and Drug Administration (FDA) to resolve clinical hold for FTX-6058 in sickle cell disease (SCD) […] The post Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023 appeared first on ForexTV... Read More
Posted: Aug 3 2023, 11:01
Author Name: forextv
Views: 080748

Search within

Pages Search Results: